Journal Mobile Options
Table of Contents
Vol. 17, Suppl. 1, 2004
Issue release date: December 2003

The Ischemic Penumbra: Identification, Evolution and Treatment Concepts

Fisher M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The concept of the ischemic penumbra is an important one for both basic investigators of cerebral ischemia and for clinicians who treat stroke patients. The ischemic penumbra has been defined in a variety of ways, but the most clinically relevant definition is that portion of the ischemic territory that is still potentially salvageable, if an appropriate treatment is given. Currently, three main challenges persist for those interested in the ischemic penumbra concept: how can this ischemic region be most accurately identified in stroke patients, what mechanisms of ischemic cell death are most important for progression from penumbra towards irreversible injury and what therapeutic modalities are most likely to impede the development of infarction? Much important information regarding each of these topics has become available recently and will be the focus of this paper.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hossmann K-A: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557–565.
  2. Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 1981;12:723–725.
  3. Hakim AM: The cerebral ischemic penumbra. Can J Neurol Sci 1987;14:557–559.
  4. Baron JC: Positron emission tomography in acute stroke; in Caplan LR (ed): Brain Ischemia: Basic Concepts and Clinical Review. Berlin, Springer, 1994, pp 19–27.
  5. Baron JC: Mapping the ischemic penumbra with PET: Implications for acute stroke treatment. Cerebrovasc Dis 1999;9:193–201.
  6. Heiss W-D, Graf R, Loftgren J, et al: Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: Residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 1997;17:388–400.
  7. Marchal G, Beaudoin V, Rioux P, et al: Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke. Stroke 1996;27:597–606.
  8. Furlan M, Marchal G, Vinder F, Derlow JM, Baron JC: Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216–226.
  9. Heiss W-D, Grond M, Thiel A, et al: Permanent cortical damage detected by flumazenil positron tomography in acute stroke. Stroke 1998;29:459–461.
  10. Neumann-Haefelin T, Moseley ME, Albers GW: New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications. Ann Neurol 2000;31:559–570.

    External Resources

  11. Schlaug G, Benfield A, Baird AE, et al: The ischemic penumbra: Operationally defined by diffusion perfusion MRI. Neurology 1999;53:1528–1537.
  12. Schellinger PD, Fieback JB, Jansen O, et al: Stroke magnetic resonance imaging within 6 h after onset of hyperacute cerebral ischemia. Ann Neurol 2001;49:460–469.
  13. Parsons MW, Barber PA, Chalk J, et al: Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28–37.
  14. Li F, Silva MD, Liu KF, et al: Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. Ann Neurol 2000;48:236–244.
  15. Kidwell CS, Saver JL, Mattiello J, et al: Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000;47:462–469.
  16. Grond M, von Kummer R, Sobesky J, Schnelling S, Heiss W-D: Early computed tomography abnormalities in acute stroke. Lancet 1997;350:1595–1596.
  17. Jungreis CA, Yonas H, Firlik AD, Wechsler LR: Advanced CT imaging (functional imaging). Neuroimag Clin North Am 1999;9:455–464.
  18. Koenig M, Kraus M, Theek C, et al: Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived from perfusion CT. Stroke 2001:32;431–437.
  19. Lee KH, Cho SJ, Byun HS, et al: Triphasic perfusion computed tomography in acute middle cerebral artery stroke. Arch Neurol 2000;57:990–999.
  20. Wintermark M, Bogousslavsky J, Thiren JP, et al: Prognostic accuracy of admission cerebral blood flow measurement by perfusion CT in acute stroke patients. Ann Neurol 2002;51:417–432.
  21. Kristian T, Siesjo BK: Calcium in ischemic cell death. Stroke 1998;29:705–718.
  22. Ye ZR, Liu KF, Garcia JH: Mechanisms of neuronal cell death after ischemic brain injury; in Fisher M, Bogousslavsky J (eds): Current Review of Cerebrovascular Disease, ed 4. Philadelphia, Current Medicine, 2001, pp 15–24.
  23. Nietera P, Lipton SA: Excitotoxins in neuronal adoptosis and necrosis. J Cereb Blood Flow Metab 1999;19:583–591.
  24. Graham SG, Chen J: Programmed cell death in cerebral ischemia. J Cereb Blood Flow Metab 2001;21:99–109.
  25. Burek MJ, Oppenheim RW: Programmed cell death in the developing nervous system. Brain Pathol 1996;6:427–446.
  26. Susis SA, Daugar E, Ravagnan L, et al: Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000;192:571–580.
  27. Mies G, Ishimaru S, Xie Y, Seo K, Hossmann K-A: Ischemic thresholds of cerebral protein synthesis and energy state following middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab 1991;22:753–761.
  28. Ankarcena M, Dypbukt JM: Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995;15:961–973.
  29. Sherman DG, Atkinson RP, Chippendale T, et al: Intravenous Ancrod for treatment of acute ischemic stroke. JAMA 2000;283:2395–2403.
  30. Furlan A, Higashida R, Wechsler LA, et al: Intraarterial prourokinase for acute ischemic stroke. The PROACT II Study: A randomized controlled trial. JAMA 1999;282:2003–2011.
  31. Fisher M, Schaebitz W: An overview of acute stroke therapy. Arch Intern Med 2000;160:3196–3200.
  32. Warach S, Pettigrew LC, Dashe JF, et al: Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 2000;48:713–722.
  33. Warach S, Sabounjian LA: ECCO 2000 study of citicoline treatment of acute ischemic stroke: Effects on infarct volume measured by MRI (abstract). Stroke 2000;31:42.
  34. Maynard KI, Quinones-Minojosa A, Matek JM: Neuroprotection against ischemia by metabolic inhibition revisited: A comparison of hypothermia, a pharmacologic cocktail and magnesium plus mexiletine. Ann NY Acad Sci 1999;890:240–254.
  35. Semenza GL: HIF-1, O2 and the PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001;107:1–3.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50